{
    "nct_id": "NCT04685135",
    "official_title": "A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.\n* Candidacy to receive treatment with docetaxel.\n\nCrossover Inclusion Criteria:\n\n* Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR\n* ECOG performance status 0-2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).\n* Active brain metastases.\n\nCrossover Exclusion Criteria:\n\n* Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.",
    "miscellaneous_criteria": ""
}